Hepcludex Mechanism Deep-Dive: Why a Lipopeptide Entry Inhibitor Cures What Antivirals Couldn't — NTCP Receptor Biology and the HBV/HDV Dependency
Bulevirtide's mechanism reveals why an entry inhibitor succeeded where small-molecule antivirals didn't. HDV is an obligate parasite of HBV — the delta virus uses the HBV envelope to assemble its virions and the HBV-derived large surface protein to enter hepatocytes via the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocyte cell membranes. Existing HBV antiviral nucleoside/nucleotide analogs (entecavir, tenofovir) suppress HBV replication but don't clear circulating HBsAg or interrupt the HDV entry cycle. Bulevirtide's 47-amino acid sequence — derived from the HBV pre-S1 domain — binds NTCP competitively and blocks both HDV and HBV entry. Real-world EU experience since 2020 shows roughly 50-60% of HDV patients achieve undetectable HDV RNA after 96 weeks of treatment, with a favorable safety profile dominated by injection-site reactions. The US approval expands access for an estimated 75,000-100,000 US patients with chronic HDV, most of whom were previously treated empirically with off-label interferon alfa with poor tolerability.